Published: May 2016 (Web posted November 2015)
Read Executive Summary
Read Full-Text Document
This practice document used the RAND/University of California, Los Angeles (UCLA) Appropriateness Method, focusing on clinical scenarios for four treatment settings for stage II and III rectal cancer: 1) appropriate neoadjuvant therapy and how it is impacted by risk classification, distance from distal tumor edge to anal verge and distance from radial tumor edge to edge of mesorectal fascia; 2) how circumferential resection margin, risk classification, distance from the anal verge and total nodal count effect choice of adjuvant therapy; 3) treatment for medically inoperable patients and the role of performance status, presence of local symptoms and distance from the anal verge; and 4) chemoradiation with or without boost in patients who sought to avoid or refused abdominoperineal resection.
Gastrointestinal Cancer-Refresher 2017 (CME)
Podcast with document chair
RAND/UCLA Appropriate Method User’s Manual